- Home
- GITS vs QNRX Comparison
GITS vs QNRX Comparison
Compare GITS & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- QNRX
- Stock Information
- Founded
- GITS 2018
- QNRX 2018
- Country
- GITS South Korea
- QNRX United States
- Employees
- GITS N/A
- QNRX N/A
- Industry
- GITS
- QNRX Medical/Dental Instruments
- Sector
- GITS
- QNRX Health Care
- Exchange
- GITS Nasdaq
- QNRX Nasdaq
- Market Cap
- GITS 4.1M
- QNRX 4.0M
- IPO Year
- GITS N/A
- QNRX N/A
- Fundamental
- Price
- GITS $2.36
- QNRX $7.37
- Analyst Decision
- GITS
- QNRX
- Analyst Count
- GITS 0
- QNRX 0
- Target Price
- GITS N/A
- QNRX N/A
- AVG Volume (30 Days)
- GITS 59.3K
- QNRX 4.3K
- Earning Date
- GITS 08-12-2025
- QNRX 08-07-2025
- Dividend Yield
- GITS N/A
- QNRX N/A
- EPS Growth
- GITS N/A
- QNRX N/A
- EPS
- GITS N/A
- QNRX N/A
- Revenue
- GITS N/A
- QNRX N/A
- Revenue This Year
- GITS N/A
- QNRX N/A
- Revenue Next Year
- GITS N/A
- QNRX N/A
- P/E Ratio
- GITS N/A
- QNRX N/A
- Revenue Growth
- GITS N/A
- QNRX N/A
- 52 Week Low
- GITS $0.87
- QNRX $5.01
- 52 Week High
- GITS $9.78
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- QNRX 37.53
- Support Level
- GITS N/A
- QNRX $6.63
- Resistance Level
- GITS N/A
- QNRX $8.69
- Average True Range (ATR)
- GITS 0.00
- QNRX 0.35
- MACD
- GITS 0.00
- QNRX -0.18
- Stochastic Oscillator
- GITS 0.00
- QNRX 26.42
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.